Clinico-radiological and Pathological Characteristics of Inflammatory Myofibroblastic Tumors in Children: A Retrospective Study

Abstract
Purpose: Inflammatory myofibroblastic tumors (IMTs) are rare, benign lesions most often seen in the lung of young adults but can occur in children, in various sites. They mimic, clinically and radiologically, malignant tumors – especially sarcomas and lymphomas. The aim was to review the clinical, radiological, and pathological data of children with a diagnosis of IMT referred to our department. Materials and Methods: This retrospective study was conducted at the Department of Medical and Paediatric Oncology, Regional Cancer Centre, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India from January 2014 to December 2015. Results: Among 288 pediatric tumors registered during the study, 5 (1.73%) had the diagnosis of IMTs. The main symptoms were abdominal distension and pain in 60% (three cases), breathlessness and cough in 20% (one case), and right axillary area swelling in 20% (one case). In three patients, complete surgical excision was done, whereas another patient with retroperitoneal mass had the residual disease and received chemotherapy followed by complete second surgery. In the case of mediastinal IMT, surgery was followed by local radiotherapy. At present, four patients are disease-free and one patient with mediastinal IMT has the residual progressive disease. Conclusion: On presentation, IMT can constitute a formidable challenge, from diagnosis through to treatment.

Keywords: Inflammatory myofibroblastic tumors, macrolides, pseudotumors, steroids, tyrosine kinase

Introduction
Inflammatory myofibroblastic tumor (IMT) is a rare clinical entity that encompasses a wide spectrum of myofibroblastic proliferation along with a varied amount of inflammatory infiltrate. First described by Brunn et al. in 1939 as a primary lung tumor, IMT can occur in nearly any body organ.[1] Previously called by many names such as inflammatory pseudotumor, fibrous xanthoma, pseudosarcoma, lymphoid hamartoma, and inflammatory myofibrohistiocytic proliferation the diverse nomenclature is mostly descriptive and reflects the uncertainty regarding true biologic nature of these lesions.[2] The term “inflammatory pseudotumor” was coined by Umiker et al. in 1954 who described four inflammatory tumors of the lung simulating xanthoma, fibroma, or plasma cell tumor. IMTs predominantly occur in children and young adults, but any age group can be affected.[3] IMTs occur more commonly in women. Although considered as benign tumors, IMTs have a propensity toward recurrence and persistent local growth.

The pathologically IMT is composed of cytologically bland spindled myofibroblasts with admixed inflammatory cells.[4] The spindle cells contain large vesicular oval nuclei with no hyperchromasias and small nucleoli. Variable amounts of pale eosinophilic cytoplasm and variable number of mitotic figures may be seen. Inflammatory cells are predominantly lymphocytes and plasma cells but may include neutrophils and eosinophils also. These cells may form germinal centers. Foamy histiocytes are occasionally present.[5] The patterns of cell mixtures may either take the form of loose or myxoid stroma with prominent vascularity or compact spindle cells or densely collagenous with fewer spindle cells and inflammatory cells.[6,7] Immunohistochemistry reveals reactivity of IMTs to actin in the majority of the cases and to vimentin in all cases reflecting the myofibroblastic nature of the cells.[8-10] Cytokeratin and desmin may be reactive in some cases.

Mohamad Hussain Mir,
Waseem Dar,
Sheikh Aejaz Aziz,
Gul Mohamad,
Burhan Wani
Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

Address for correspondence:
Dr. Waseem Dar,
Department of Medicine,
Oncology Division,
Sher-I-Kashmir Institute of Medical Sciences,
Soura, Srinagar - 190 011,
Jammu and Kashmir, India.
E-mail: drwaseem.mw@gmail.com

Access this article online
Website: www.ijmpo.org
DOI: 10.4103/ijmpo.ijmpo_178_16
Quick Response Code:

Aims and objectives

1. To describe the prevalence and clinical, radiological, and pathological characteristics of inflammatory fibroblastic tumors in children.

Materials and Methods

This study was carried out in the Department of Medical Oncology Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India, which is one of the astute tertiary care centers in North India with a dedicated Regional Cancer Centre (RCC) catering to the needs of more than 13 million people. In this study, all the pediatric cancer patients registered with RCC from January 2014 to December 2015 were included in the study. All the clinical signs and symptoms and relevant diagnostic methods and their results of patients with a diagnosis of the inflammatory fibroblastic tumor were documented, and their treatment details noted.

Results

Among 288 pediatric tumors registered during the study, 5 (1.73%) had the diagnosis of IMTs. There were three male and two female children (M:f ratio 1.5:1). The mean age was 5.32 years (range: 2–9 years). The main symptoms were abdominal distension and pain in 60% (three cases), breathlessness and cough in 20% (one case), and right axillary area swelling in 20% (one case). On computed tomography of chest and abdomen, one patient had mediastinal widening with the impression of lymphoma, two patients were labeled as having retroperitoneal sarcoma, and one patient had an ileal growth with the impression of Burkitt lymphoma [Figures 1-3].

In one patient with right axillary swelling, lymphoma was suspected. In only one patient (20%), initial histopathology was reported as IMT (retroperitoneal lesion), whereas in rest of the cases, it was only after review with immunohistochemistry from an oncopathologist that diagnosis of IMT was made. On immunohistochemistry, in all patients, tumor cells were strongly positive for smooth muscle actin, desmin, and anaplastic lymphoma kinase (ALK)-1 and negative for CD-34, CD-117, discovered on GIST and S100. In three patients, complete surgical excision was done (one with axillary mass and two with abdominal disease). One patient with retroperitoneal mass had residual disease and received chemotherapy followed by complete second surgery. In the case of mediastinal IMT, surgery was followed by local radiotherapy. At present, four patients are disease-free and one patient with mediastinal IMT has residual progressive disease. The summary of this study is given in Table 1.

Discussion

IMT is a rare tumor of childhood and adolescence. Although they occur predominantly in lung, they may occur in any organ. Extrapulmonary IMT occurs commonly in the abdomen or in soft tissues but may occur anywhere. Surprisingly, in our study, there was no pulmonary IMT; instead, there was one mediastinal IMT, two retroperitoneal,
one axillary, and one ileocecal. This may be due to overall low prevalence of IMTs. These lesions are great mimickers and may escape diagnosis. Oeconomopoulou et al. reported a young child who was initially diagnosed to have acute appendicitis but on laparotomy was found to have a tumor that was histology and immunohistochemistry was found to be IMT. Similarly, in our case, none of the patients was initially suspected to have IMT. In fact, ileal IMT in our study was reported as lymphoma initially and only on review histopathology and immunohistochemistry was found to be IMT. Yang et al. reported a 56-year-old man with IMT at the left carotid bifurcation accompanied by recurrent syncope and falls. The patient underwent surgery after which corticosteroids and antibiotics were administered for a short-term. No recurrence was observed during the 2-year follow-up. Other unusual presentations include breast lumps, maxillary sinus tumors, renal masses, pemphigus, etc. Sometimes, they may occur with another clinical condition like sclerosing cholangitis or as a part of double malignancy such as Hodgkin’s lymphoma, small cell lung cancer, Wilms tumor, and many others.

The signs and symptoms of IMTs largely depend on the site of involvement. Occasionally, they may be completely silent, discovered incidentally on routine imaging or on the evaluation of an inflammatory response at laboratory examination. Grossly, the tumors are circumscribed but not encapsulated and appear as white tan masses with whorled fleshy or myxoid cut surface and may have focal hemorrhage, necrosis, or calcification. Average size is 6 cm. Microscopically these tumors comprise myofibroblastic and fibroblastic spindle cells with inflammatory infiltrate of lymphocytes, plasma cells, eosinophils, and histiocytes against a background of abundant blood vessels. Three patterns have been described. In one pattern, there are elongated myofibroblasts containing abundant eosinophilic cytoplasm and vesicular nuclei, loose myxoid stroma with neutrophils, lymphocytes, and eosinophils, but few plasma cells. Another pattern comprises spindled myofibroblasts and fibroblasts in more compact stroma, arranged as islands surrounded by fibromyxoid stroma with prominent plasma cells and mitotic figures. The third pattern has a densely hyalinized stroma with a few spindle cells; a few plasma cells or lymphocytes. All three patterns have no nuclear pleomorphism and no atypical mitotic figures. Malignant behavior is associated with highly atypical polygonal cells with oval nuclei, prominent nucleoli, Reed–Sternberg-like cells and atypical mitotic figures. Approximately 50%–70% of the tumors harbor ALK gene rearrangement, leading to the formation of a chimeric fusion protein, which is detectable by immunohistochemistry or FISH. ALK is a receptor-type protein tyrosine kinase, which is rendered oncogenic either as a result of a gene fusion, such as in anaplastic large cell lymphoma, lung cancer, and IMT or due to a missense mutation as seen in neuroblastoma and anaplastic thyroid cancer. ALK expression and/or ALK gene rearrangement was previously described as a good prognostic marker in IMT, with positive cases showing a better outcome, whereas ALK-negative IMTs being more aggressive with a higher frequency of metastasis compared with ALK-positive IMT. Previously, due to its markedly variable phenotype and lack of objective immunoprofile, the diagnosis of ALK-negative IMTs has been often a diagnosis of exclusion. In a recent study using next generation sequencing, six of nine ALK-negative IMT tumors showed the presence of fusions in ALK, ROS1, or PDGFRB, suggesting that IMT is largely a kinase fusion – driven neoplasm. The study was initiated by the dramatic response to the ROS1 inhibitor crizotinib in an index case of a treatment-refractory ALK-negative IMT pediatric patient.

### Table 1: Clinico-radiological characteristics of inflammatory myofibroblastic tumor patients in our study

<table>
<thead>
<tr>
<th>Patients characteristic</th>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
<th>Case 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Male</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Signs and symptoms</td>
<td>Abdominal distension pain</td>
<td>Breathlessness cough</td>
<td>Abdominal distension pain</td>
<td>Abdominal distension pain</td>
<td>Right axillary area swelling</td>
</tr>
<tr>
<td>Radiology</td>
<td>Retroperitoneal mass</td>
<td>Mediastinal widening with CT suggestive of lymphoma</td>
<td>Retroperitoneal mass</td>
<td>Ileocecal growth</td>
<td></td>
</tr>
<tr>
<td>Immunohistochemistry</td>
<td>Strongly positive for SMA, desmin, and ALK-1 and negative for CD-34, CD-117, DOG-1 and S100</td>
<td>Strongly positive for SMA, desmin, and ALK-1 and negative for CD-34, CD-117, DOG-1 and S100</td>
<td>Strongly positive for SMA, desmin, and ALK-1 and negative for CD-34, CD-117, DOG-1 and S100</td>
<td>Strongly positive for SMA, desmin, and ALK-1 and negative for CD-34, CD-117, DOG-1 and S100</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>Complete surgical excision</td>
<td>Surgery followed by local radiotherapy</td>
<td>Surgery followed by chemotherapy and then second surgery</td>
<td>Complete surgical excision</td>
<td>Complete surgical excision</td>
</tr>
<tr>
<td>Follow up</td>
<td>Disease free</td>
<td>Residual disease</td>
<td>Disease free</td>
<td>Disease free</td>
<td>Disease free</td>
</tr>
</tbody>
</table>

CT – Computed tomography; SMA – Smooth muscle actin; ALK – Anaplastic lymphoma kinase; DOG – Discovered on GIST.
There are no clear guidelines regarding the treatment of IMTs. The heterogeneity of these tumors is reflected by the number of treatment options employed by physicians worldwide ranging from surgery to steroids to immunomodulators. Since IMTs usually mimic other tumors in presentation, surgery is usually employed initially with further treatment options followings histopathological diagnosis and immunohistochemistry and cytogenetics. Chemotherapy is recommended when IMT is multifocal, invasive or shows local recurrence. It is often a combination of agents including methotrexate, cisplatin, vinorelbine, Adriamycin, carboplatin, and paclitaxel given with a view of achieving complete remission. Since IMTs involve an inflammatory response, several clinicians have employed nonsteroidal anti-inflammatory agents in their management and found good results. [29] Chaves et al. investigated the anti-inflammatory action of nonsteroidal anti-inflammatory drugs (NSAIDs). The authors analyzed reports of ALK-negative cases receiving NSAID therapy and reported the striking result that NSAIDs were effective in treating ten of 11 cases of IMT. Besides several cases of IMTs have been treated with antibiotics alone. Since Macrolide antibiotics are known to possess anti-inflammatory activities, they have been used as a treatment option in the management of IMTs. [30] Watanabe et al. reported a 73-year-old female patient with ALK-negative primary pulmonary IMT who went into remission on treatment with clarithromycin. [31] Similarly, Alezra et al. reported a case of an 8-year-old girl with documented bladder IMT that resolved completely after antibiotic therapy. Since tyrosine kinase mutations are found in IMTs crizotinib has been used by some physicians in the treatment of chemotherapy-resistant disease.

**Conclusion**

IMT is a unique clinical condition that has confused clinicians and pathologists alike. The disease has a significant diversity in clinical presentation, behavior, histopathology, and treatment options. Although in some cases, the disease may even regress spontaneously, in majority treatment in the form of surgery, chemotherapy, steroids, or immunomodulators is employed; the latter options employed when disease shows local recurrence or distant metastasis.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

19. Johnson K, Notrica DM, Carpentieri D, Jaroszewski D,


